Skip to main content

J0791 HCPCS Level II Code: Injection, crizanlizumab-tmca, 5 mg

Coding at a Glance

Drug products
1 NDC product
CMS cross-references
1 related code

Medicare Coverage & Payment

  • CMS short descriptor: Inj crizanlizumab-tmca 5mg
  • Medicare coverage: Carrier judgment (CMS coverage code C)
  • Payment category: Drugs (pricing indicator 51)
  • BETOS: O1E — Other drugs
  • Last CMS action effective: July 1, 2020

Source: CMS HCPCS Level II release. Coverage codes indicate how Medicare treats the code, not whether a specific claim will be paid; payer policy and documentation still govern.

Change history

  • July 1, 2020
    Added to the code set
    Injection, crizanlizumab-tmca, 5 mg

Related Codes

CMS cross-reference from deleted or non-Medicare codes

The CMS HCPCS Level II code set cross-references these codes (deleted or not valid for Medicare) to this code.

C9053 — Injection, crizanlizumab-tmca, 1 mg

Drug products (NDC)

CMS ASP NDC-HCPCS Crosswalk · 2026 Q3

Medicare Part B payment limit (ASP + 6%): $129.94

00078-0883-61 — Adakveo — Novartis Pharmaceuticals Corporation (size 10 × qty 1 (5 MG per billing unit))

From the CMS ASP NDC-HCPCS Crosswalk and Part B Payment Limit File. Payment limits apply per HCPCS billing code, not per package.

Contextual Map

Every relationship of J0791 in one view: hierarchy, official tabular instructions in both directions, clinical classification, risk adjustment, MS-DRG participation, index terms and change history — each edge carrying the CMS source it derives from.

Nearest codes (34)

CMS cross-reference

Change history

  • July 1, 2020 — Added to the code set [Change history]

Nearest Codes in This Family

Official HCPCS Level II classifications closest to J0791 in its code family, with their registry titles.